 Antineoplastic Agents
"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antitumor Drugs
- Drugs, Antitumor
- Antitumor Agents
- Agents, Antitumor
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 6 | 6 | 12 | | 1981 | 5 | 3 | 8 | | 1982 | 9 | 4 | 13 | | 1983 | 6 | 1 | 7 | | 1984 | 3 | 0 | 3 | | 1985 | 2 | 1 | 3 | | 1986 | 4 | 2 | 6 | | 1987 | 3 | 2 | 5 | | 1988 | 6 | 0 | 6 | | 1989 | 6 | 2 | 8 | | 1990 | 2 | 3 | 5 | | 1991 | 3 | 1 | 4 | | 1992 | 6 | 5 | 11 | | 1993 | 7 | 1 | 8 | | 1994 | 12 | 2 | 14 | | 1995 | 6 | 2 | 8 | | 1996 | 13 | 3 | 16 | | 1997 | 8 | 1 | 9 | | 1998 | 24 | 7 | 31 | | 1999 | 10 | 9 | 19 | | 2000 | 19 | 9 | 28 | | 2001 | 25 | 7 | 32 | | 2002 | 41 | 14 | 55 | | 2003 | 34 | 12 | 46 | | 2004 | 42 | 14 | 56 | | 2005 | 34 | 21 | 55 | | 2006 | 43 | 20 | 63 | | 2007 | 51 | 20 | 71 | | 2008 | 38 | 19 | 57 | | 2009 | 45 | 26 | 71 | | 2010 | 61 | 29 | 90 | | 2011 | 64 | 20 | 84 | | 2012 | 58 | 27 | 85 | | 2013 | 57 | 25 | 82 | | 2014 | 74 | 25 | 99 | | 2015 | 78 | 36 | 114 | | 2016 | 65 | 30 | 95 | | 2017 | 47 | 27 | 74 | | 2018 | 42 | 26 | 68 | | 2019 | 48 | 23 | 71 | | 2020 | 29 | 15 | 44 | | 2021 | 13 | 4 | 17 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Derman BA, Davis AM. Recommendations for Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy. JAMA. 2021 Sep 21; 326(11):1058-1059.
-
Feldman RC, Hyman DA, Price WN, Ratain MJ. Negative innovation: when patents are bad for patients. Nat Biotechnol. 2021 08; 39(8):914-916.
-
Chen D, Xia S, Zhang R, Li Y, Famulare CA, Fan H, Wu R, Wang M, Zhu AC, Elf SE, Su R, Dong L, Arellano M, Blum WG, Mao H, Lonial S, Stock W, Odenike O, Le Beau M, Boggon TJ, He C, Chen J, Gao X, Levine RL, Chen J. Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. Mol Cell. 2021 09 16; 81(18):3833-3847.e11.
-
Huang L, Zhao L, Zhang J, He F, Wang H, Liu Q, Shi D, Ni N, Wagstaff W, Chen C, Reid RR, Haydon RC, Luu HH, Shen L, He TC, Tang L. Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways. Aging (Albany NY). 2021 07 07; 13(13):17407-17427.
-
Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, Stein AS, Stone RM, Winer ES, Seet CS, Döhner H, Pollyea DA, McCloskey JK, Odenike O, Löwenberg B, Ossenkoppele GJ, Patel PA, Roshal M, Frattini MG, Lersch F, Franovic A, Nabhan S, Fan B, Choe S, Wang H, Wu B, Hua L, Almon C, Cooper M, Kantarjian HM, Tallman MS. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021 04 01; 137(13):1792-1803.
-
Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf D. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia. 2021 07; 35(7):2076-2085.
-
Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y, Mariathasan S, Grivas P, Drakaki A, O'Donnell PH, Rosenberg JE, Geynisman DM, Petrylak DP, Hoffman-Censits J, Bedke J, Kalebasty AR, Zakharia Y, van der Heijden MS, Sternberg CN, Davarpanah NN, Powles T. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 04; 22(4):525-537.
-
Larson RA, Mandrekar SJ, Huebner LJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Voso MT, Klisovic RB, Galinsky I, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Gathmann I, Döhner H, Stone RM. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia. 2021 09; 35(9):2539-2551.
-
Yang K, Hou Y, Zhang Y, Liang H, Sharma A, Zheng W, Wang L, Torres R, Tatebe K, Chmura SJ, Pitroda SP, Gilbert JA, Fu YX, Weichselbaum RR. Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation. J Exp Med. 2021 03 01; 218(3).
-
Passaro A, Bestvina C, Velez Velez M, Garassino MC, Garon E, Peters S. Severity of COVID-19 in patients with lung cancer: evidence and challenges. J Immunother Cancer. 2021 03; 9(3).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|